Raymond James Financial Services Advisors Inc. purchased a new position in shares of Chemed Co. (NYSE:CHE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,280 shares of the company’s stock, valued at approximately $259,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Chemed by 1.9% during the second quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock worth $374,435,000 after buying an additional 34,938 shares during the period. State Street Corp increased its position in Chemed by 1.8% during the second quarter. State Street Corp now owns 453,605 shares of the company’s stock worth $92,782,000 after buying an additional 8,238 shares during the period. Voya Investment Management LLC increased its position in Chemed by 39.7% during the second quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock worth $43,926,000 after buying an additional 61,056 shares during the period. Thrivent Financial For Lutherans increased its position in Chemed by 0.3% during the second quarter. Thrivent Financial For Lutherans now owns 171,350 shares of the company’s stock worth $35,046,000 after buying an additional 490 shares during the period. Finally, Principal Financial Group Inc. increased its position in Chemed by 0.8% during the second quarter. Principal Financial Group Inc. now owns 133,232 shares of the company’s stock worth $27,250,000 after buying an additional 995 shares during the period. 97.75% of the stock is currently owned by institutional investors.
Chemed Co. (NYSE CHE) opened at $238.65 on Friday. Chemed Co. has a 12 month low of $151.23 and a 12 month high of $251.00. The firm has a market capitalization of $3,810.29, a P/E ratio of 29.39, a price-to-earnings-growth ratio of 5.05 and a beta of 1.16. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15.
Chemed (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.15. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The company had revenue of $417.40 million for the quarter, compared to the consensus estimate of $414.34 million. During the same period last year, the business posted $1.73 EPS. The company’s revenue was up 6.3% on a year-over-year basis. equities research analysts predict that Chemed Co. will post 4.73 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Monday, December 4th. Shareholders of record on Monday, November 13th were paid a $0.28 dividend. The ex-dividend date was Friday, November 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.47%. Chemed’s dividend payout ratio (DPR) is currently 24.89%.
In related news, VP Naomi C. Dallob sold 750 shares of Chemed stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $222.09, for a total value of $166,567.50. Following the sale, the vice president now directly owns 9,097 shares in the company, valued at $2,020,352.73. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Patrick P. Grace sold 500 shares of Chemed stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $201.48, for a total value of $100,740.00. Following the completion of the sale, the director now owns 4,515 shares in the company, valued at $909,682.20. The disclosure for this sale can be found here. Insiders sold a total of 46,179 shares of company stock worth $10,729,699 over the last quarter. Company insiders own 4.90% of the company’s stock.
Several research analysts have weighed in on CHE shares. National Bank Financial upgraded Chemed from a “sector perform market weight” rating to an “outperform market weight” rating in a research note on Sunday, August 13th. Royal Bank Of Canada reiterated a “hold” rating and issued a $209.00 target price on shares of Chemed in a research note on Tuesday, October 3rd. Zacks Investment Research downgraded Chemed from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. ValuEngine downgraded Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, KeyCorp started coverage on Chemed in a research note on Monday, August 28th. They issued a “sector weight” rating on the stock. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Chemed currently has an average rating of “Hold” and an average price target of $236.00.
ILLEGAL ACTIVITY NOTICE: “Raymond James Financial Services Advisors Inc. Invests $259,000 in Chemed Co. (CHE) Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/10/raymond-james-financial-services-advisors-inc-invests-259000-in-chemed-co-che-stock.html.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Co. and related companies with MarketBeat.com's FREE daily email newsletter.